- 11-50 Employees
- Based in Chatswood, Australia
Noxopharm is an Australian-based clinical-stage drug development company with offices in Sydney and New York. Veyonda is the first pipeline drug candidate which is being trialed as a treatment for a broad range of solid tumor cancers and for septic shock. Later generation drug candidates for large markets of unmet medical need are being developed in an active R&D program.
REPORT RATINGS4.8 / 5.0 (90)
Noxopharm reports have an aggregate usefulness score of 4.8 based on 90 reviews.
Most Recent Annual Report
2022 Annual Report
Older/Archived Annual Reports